The largest database of trusted experimental protocols

8 protocols using mk571

1

Synthesis of Pranlukast Analogues

Check if the same lab product or an alternative is used in the 5 most similar protocols
A similar preparation to that by Raposo et al. (1996) and Green et al. (Geen et al., 2006 ) was followed for synthesis of pranlukast analogues. A detailed description of compound synthesis and compound characterisation can be found in the associated supporting information section. Pranlukast, zafirlukast and montelukast were purchased from AK-Scientific. Cinalukast, FPL 55712, SR 2640, and MK 571 were purchased from Tocris.
+ Open protocol
+ Expand
2

Investigating Adenylyl Cyclase Regulation

Check if the same lab product or an alternative is used in the 5 most similar protocols
N-acetyl cysteine and ATP were purchased from Sigma, Glutathione monoethyl ester from Calbiochem, KH7 and SQ22536, forskolin, Inhibitor-172, MK571 and irinotecan were purchased from Tocris. [14C] 6-Mercaptopurine (6-MP) (51 mCi/mmol) was derived from Moravek Biochemicals, CA. ADCY1, 3,6,7,9 and10 adenylyl cyclase antibodies were purchased from Abcam.
+ Open protocol
+ Expand
3

Fluorescence Imaging of ABC Transporters

Check if the same lab product or an alternative is used in the 5 most similar protocols
NBD-CSA was custom synthesized [3 (link), 8 (link), 12 (link)]. Bodipy-Prazosin was purchased from Life Technologies (Grand Island, NY). Sulforhodamine 101 free acid (Texas Red), 4 % paraformaldehyde, 0.2% glutaraldehyde, Triton X-100 and D-glucose were purchased from Sigma-Aldrich (St. Louis, MO). Valspodar (PSC-833), KO143 and MK571 were purchased from Tocris Bioscience (Ellisville, MO). All the reagents used in this study were analytical or best available pharmaceutical grade.
+ Open protocol
+ Expand
4

Small Molecule Acquisition and Preparation

Check if the same lab product or an alternative is used in the 5 most similar protocols
JZL184 (Cat. no. 13158; ≥97% purity) was purchased from Cayman Chemical. ML239 (SML0442; ≥98%), NSC23766 (SML0952; ≥97%), CP-100356 (PZ0171; ≥98%), elacridar (SML0486; ≥98%), ML210 (SML0521; ≥98%), ferrostatin-1 (SML0583; ≥95%), α-tocopherol (T3251; ≥99%), and N-acetyl-L-cysteine (A7250; ≥99%) were purchased from Sigma. YM-155 (S1130; ≥99%), obatoclax mesylate (S1057; ≥99%), and RITA (S2781; 99%) were purchased from SelleckChem. SC-26196 (4189; 99.2%), quercetin (1125; >98%), and MK-571 (2238; >96.9%) were purchased from Tocris. Austocystin D was purchased from eMolecules. The selective CYP2J2 inhibitor 1-(4-bromophenyl)-4-[4-(hydroxydiphenylmethyl)piperidin-1-yl]butan-1-one was synthesized in-house according to the published methodology (>95% purity)48 (link). All small molecules were dissolved in DMSO, except N-acetylcysteine, which was dissolved in cell culture medium then adjusted to pH 7.5.
+ Open protocol
+ Expand
5

Functional Assays for MRP1 and BCRP

Check if the same lab product or an alternative is used in the 5 most similar protocols
Calcein AM (ThermoFisher, NY, USA) cellular accumulation assays were used for MRP1 function, while BCRP function was assessed with Hoechst 33342 (ThermoFisher, NY, USA). MK571 (Tocris, Bristol, UK) and KO143 (Tocris, Bristol, UK), specific MRP1 and BCRP inhibitors, respectively, were used in the functional assay. M1, M2, and unstimulated U937 cells were washed and resuspended in serum-free RPMI, and then seeded in 96-well Black Clear-Bottom Plates (Costar, Washington, DC, USA). Plates were incubated at 37°C with or without inhibitor (MK571, 10 min incubation; KO143, 2 h incubation). After incubation, 10 μM Calcein AM or 10 μM Hoechst 33342 was added to the plate. Plates were immediately placed in an FLx800 Fluorescence Reader (BioTek, Winooski, VT, USA) for 60 min, and read at 485/528 (ex/em). Cell viability was determined via trypan blue staining.
+ Open protocol
+ Expand
6

Small Molecule Acquisition and Preparation

Check if the same lab product or an alternative is used in the 5 most similar protocols
JZL184 (Cat. no. 13158; ≥97% purity) was purchased from Cayman Chemical. ML239 (SML0442; ≥98%), NSC23766 (SML0952; ≥97%), CP-100356 (PZ0171; ≥98%), elacridar (SML0486; ≥98%), ML210 (SML0521; ≥98%), ferrostatin-1 (SML0583; ≥95%), α-tocopherol (T3251; ≥99%), and N-acetyl-L-cysteine (A7250; ≥99%) were purchased from Sigma. YM-155 (S1130; ≥99%), obatoclax mesylate (S1057; ≥99%), and RITA (S2781; 99%) were purchased from SelleckChem. SC-26196 (4189; 99.2%), quercetin (1125; >98%), and MK-571 (2238; >96.9%) were purchased from Tocris. Austocystin D was purchased from eMolecules. The selective CYP2J2 inhibitor 1-(4-bromophenyl)-4-[4-(hydroxydiphenylmethyl)piperidin-1-yl]butan-1-one was synthesized in-house according to the published methodology (>95% purity)48 (link). All small molecules were dissolved in DMSO, except N-acetylcysteine, which was dissolved in cell culture medium then adjusted to pH 7.5.
+ Open protocol
+ Expand
7

Compound Screening for Ion Channel Modulators

Check if the same lab product or an alternative is used in the 5 most similar protocols
All materials were obtained from Sigma-Aldrich® (St. Louis, MO) unless otherwise specified. Tetrodotoxin was purchased from Calbiochem, EMD Biosciences (La Jolla, CA). MK571, T16Ainh-A01, Eact and albuterol were purchased from Tocris (Minneapolis, MN). Membrane potential dye [fluorescent imaging plate reader (FLIPR) blue reagent] was obtained from Molecular Devices (Sunnyvale, CA). Fura-2, AM and mag-fluo-4, AM were obtained from Molecular Probes. B25 (5-[(2,6-difluorobenzyl)oxy]-2-(2-naphthyl)benzofuran-3-carboxylic acid) was synthesized as in Kumar et al.17 (link) MONNA (N-((4-methoxy)-2-naphthyl)-5-nitroanthranilic acid) was a gift from Dr. C. Justin Lee from Korea Institute of Science and Technology.
+ Open protocol
+ Expand
8

Propranolol Uptake Inhibition Assay

Check if the same lab product or an alternative is used in the 5 most similar protocols
Cells were pre-incubated with inhibitor at a concentration 100 times higher (400 nM) than that of propranolol to competitively inhibit the membrane channel. Amantadine (Sigma, CAS no. 768-94-5), cimetidine (ICN, CAS no. 51481-61-9), cyclosporine A (Fluka, CAS no. 59865-13-3), MK571 (Tocris Biosciences, CAS no. 115104-28-4), quinidine (Sigma, CAS no. 56-54-2) or verapamil hydrochloride (Fluka, CAS no. 152-11-4) were dissolved in DMSO (0.1% in final solution) and added to the apical (in 0.75 mL freshwater) or basal (in 1.0 mL L-15 medium). Controls and compartments without inhibitor contained 0.1% DMSO. After 1 h, volumes were replaced with 1.5 mL freshwater containing 1 μg L−1 (4 nM) propranolol apically and 2.0 mL L-15 basally, whilst keeping the final concentration of inhibitor at 400 nM throughout. The same sampling procedure as for BTA at time 0, 6 (not for cyclosporine A), 24, 36 and 48 h proceeded and the uptake Papp of propranolol was calculated using Eq. (2). The Papp in all inhibitor-free controls were expressed as a percentage of the mean (100%) and the change in uptake Papp (inhibition) in the presence of inhibitors was expressed as a percentage of this mean control.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!